Results 1 - 20 of 600 in Wyeth
-
Wyeth shares rises on promising study of Alzheimer's drug
The drug maker Wyeth said Tuesday that an investigational product for treating Alzheimer's showed promise in an intermediate clinical study.
Comment?
-
Wyeth, Progenics Drug Clears EC
... treatment for opioid-induced constipation (OIC), has been approved by the European Commission. The drug, developed by Wyeth and Progenics , is now approved in the 27 member states of the European Union as well as Iceland, Norway, and Liechtenstein. ...
Comment?
-
Wyeth and Progenics announces receipt of approval from European...
Wyeth and Progenics announces receipt of approval from European Commission of RELISTOR as a treatment for OIC Published in M2 EquityBites on Friday, 04 July 2008 at 13:19 GMT Wyeth Pharmaceuticals, a provider ...
Comment?
-
Wyeth and Progenics Receive Approval from European Commission for...
Wyeth Pharmaceuticals, a division of Wyeth , and Progenics Pharmaceuticals, Inc.
Comment?
-
Wyeth Pharmaceuticals-Progenics drug Relistor OK'd in Europe
Wyeth Pharmaceuticals and Progenics Pharmaceuticals Inc. received marketing approval from the European Commission Thursday for Relistor, a treatment of opioid-induced constipation in advanced illness patients ...
Comment?
-
Myriad's Small Billion-Dollar Loss
... large market potential for drugs with even modest efficacy effects, it is understandable why a company like Myriad or Wyeth (NYSE: WYE ) and Elan (NYSE: ELN ) would bring these compounds into phase 3 testing with less than unblemished data from ...
Comment?
-
FDA News Gives Glaxo a Glimmer of Hope
... Gardasil has recently seen FDA setbacks of its own. Vaccines are the bedrock supporting multiple drugmakers, including Wyeth (NYSE: WYE ) and Sanofi-Aventis (NYSE: SNY ) . While it's unfortunate for Glaxo that it will have to wait until at least ...
Comment?
-
Drug trial defies Wall Street's 'wisdom'
... offer hope to millions of Alzheimer's patients. When the market opened Tuesday, both Elan ( ELN , news , msgs ) and Wyeth ( WYE , news , msgs ) traded up as much as 7% as the results of their Phase II trial for AAB-001 hit the newswires. Then ...
Comment?
-
Alzheimer's Failure For Myriad Genetics
... further outperforms expectations." Myriad shares rose in mid-June after Elan (nyse: ELN - news - people ) and Wyeth (nyse: WYE - news - people ) reported positive results for their Alzheimer's drug candidate, bapineuzumab (See " Elan and Wyeth ...
Comment?
-
Wyeth Sets Webcast and Conference Call for 2008 Second Quarter Earnings
On Wednesday, July 23, 2008, Wyeth will announce financial results for the 2008 second quarter.
Comment?
-
Monday Options Update: C, MYGN, TSN, LLTC, F, GM, BEC, RNWK
... treating symptoms of the disease), and after promising clinical results for similar drugs from Elan Corp ( ELN ) and Wyeth ( WYE ) earlier this month, the market was looking for validation of the anti-amyloid therapeutic concept with Myriad's ...
Comment?
-
Health-Care Funds Are Ailing in 2008
... of 143 companies, including Johnson & Johnson ( JNJ ), Pfizer ( PFE ), Abbott Laboratories ( ABT ), Merck ( MRK ) and Wyeth ( WYE ). The fund charges a cheap $48 for every $10,000 invested. Any time an investor is dealing with a sector it probably ...
Comment?
-
Wyeth shares rises on promising study of Alzheimer's drug
The drug maker Wyeth said Tuesday that an investigational product for treating Alzheimer's showed promise in an intermediate clinical study.
Comment?
-
Wyeth CEO Poussot takes chairman seat
Madison drug-maker Wyeth announced that Bernard Poussot, its president and CEO, will take on the additional role of chairman, effective immediately.
Comment?
-
Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
Wyeth has announced that Bernard Poussot, 56, Wyeth's President and Chief Executive Officer, has assumed the additional position of Chairman of the Board, effective today.
Comment?
-
Wyeth CEO Bernard Poussot takes on chairman role
Drug maker Wyeth said Friday President and Chief Executive Bernard Poussot will take on the added role of chairman, effective immediately.
Comment?
-
Wyeth Declares Common and Preferred Stock Dividends
At a meeting of its Board of Directors, held today, Wyeth declared dividends on both the Common and Preferred Stock of the Company.
Comment?
-
Northern Trust Casts NETS Over Celtic Tiger
... pattern on June 17. The stock soared last week on news that a new Alzheimer's drug, in development with Wyeth , ( WYE ) helped a large patient test group. Macro Picture The ISEQ 20 Index has fallen 25% year to date, as of Tuesday. It has lost 46% in ...
Comment?
-
More Than Momentum: Stocks Rising for a Reason
... Elan has been trending up after a preview of some results from tests of its mid-stage Alzheimer's drug with partner Wyeth (NYSE: WYE ) last week. Some analysts concluded that the drug appears to help treat a large percentage of patients with the ...
Comment?
-
Elan, Wyeth: Response to Skeptics on Alzheimer's Data
Elan and Wyeth presented their phase II data on June 17th with bapineuzumab in Alzheimer's Disease.
Comment?
Wyeth Forum
Most Popular
